Clinical Trial

Trial of Ixazomib for Kaposi Sarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2020-03-11; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2023-11-07
Status change: Suspended → Not Yet Recruiting 2023-03-28
Status change: Recruiting → Suspended 2022-06-02
Status change: Not Yet Recruiting → Recruiting 2020-11-30
Trial Details
NCT Number NCT04305691
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI)
Conditions Kaposi Sarcoma, Skin
Enrollment 41 participants
Start Date 2023-11-07
Primary Completion 2029-03-15 (estimated)
Study Completion 2029-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-27